TABLE 1.

Fluconazole susceptibilities of 426 isolates of Candida spp. as determined by the VITEK 2 yeast susceptibility test and by CLSI BMD methodsa

SpeciesNo. testedTest methodbMIC (μg/ml)cEA (%)d
Range50%90%
C. albicans198VITEK 2≤1-≥64≤1≤1
BMD-24≤0.12-≥1280.250.597.0
BMD-48≤0.12-≥1280.250.596.5
C. dubliniensis8VITEK 2≤1-32≤1
BMD-24≤0.12-16≤0.12100.0
BMD-48≤0.12-160.25100.0
C. glabrata83VITEK 2≤1-≥648≥64
BMD-240.5-≥12846498.8
BMD-480.5-≥12816≥12896.4
C. guilliermondii3VITEK 2≤1-42
BMD-241-44100.0
BMD-482-44100.0
C. krusei51VITEK 2≤1-≥641632
BMD-24≤1-≥1281632100.0
BMD-48≤1-≥12864≥12868.6
C. lusitaniae9VITEK 2≤1-21
BMD-24≤0.12-10.5100.0
BMD-48≤0.12-20.5100.0
C. norvegensis1VITEK 28
BMD-2416100.0
BMD-4816100.0
C. parapsilosis43VITEK 2≤1-≥64≤12
BMD-240.25-40.5195.3
BMD-480.5-41297.7
C. pelliculosa2VITEK 22-42
BMD-242-42100.0
BMD-4844100.0
C. tropicalis28VITEK 2≤1-8≤1≤1
BMD-24≤0.12-80.251100.0
BMD-480.25-160.54100.0
All Candida spp.426VITEK 2≤1-≥64≤116
BMD-24≤0.12-≥1280.51697.9
BMD-48≤0.12-≥1280.56493.7
  • a Isolates included both clinical (n = 346) and challenge (n = 80) sets.

  • b BMD-24 and BMD-48, BMD performed at 24 h and 48 h of incubation, respectively.

  • c 50% and 90%, MICs encompassing 50% and 90% of isolates tested, respectively.

  • d % EA is the EA (±2 log2 dilutions) between VITEK 2 and BMD MICs.